PPP-02: (-)-EPICATECHIN REDUCES ALLODYNIA IN RATS WITH PAINFUL DIABETIC NEUROPATHY

J Pharm Pharmacogn Res 3(suppl. 1): S94, 2015

Proceedings of the 4th International Symposium on Pharmacology of Natural Products FAPRONATURA 2015  September 21st-25th, 2015; Cuban Society of Pharmacology. Topes de Collantes, Sancti Spiritus, Cuba.

Poster

PPP-02: (-)-EPICATECHIN REDUCES ALLODYNIA IN RATS WITH PAINFUL DIABETIC NEUROPATHY

Quiñonez-Bastidas GN1, Calcutt NA, Frizzi K, Rocha-González HI2 Granados-Soto V1, Murbartián J1.

1Departamento de Farmacobiología, Cinvestav, Sede Sur, México, D.F., México. Calzada de Los Tenorios #235, Granjas Coapa, Tlalpan, 14330. E-mail: geovanna_quinonez@hotmail.com Tel: (55)-54832800 ext:1214.
2Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina del Instituto Politécnico Nacional, México, D.F., México.
3Department of Pathology, University of California San Diego, La Jolla, CA 92093, USA.

 

Introduction: The Painful Diabetic Neuropathy (PDN) is among the most debilitating consequences of chronic diabetes, with a prevalence estimated up to 34% in diabetic population. Allodynia, sensory loss and motor nerve deficit are included within the symptoms described by diabetic patients. The treatment of PDN is frequently unsatisfactory. It has been suggested that antioxidant therapy could be an approach to relief PDN. The antioxidant drug (-)-epicatechin has shown effects in attenuate inflammatory pain in a mouse model. The aim of this study was to investigate the (-)-epicatechin’s effect on allodynia, sensory loss and motor nerve deficit in rats subjected to painful diabetic neuropathy (PDN). Methods: Female Wistar rats (220-240 g) were injected with streptozotocin (STZ) (50 mg/kg, i.p.) to produce experimental diabetes. Results: After 8 weeks, the chronic treatment with (-)-epicatechin (3 mg/kg, i.p.) prevented tactile allodynia and partially motor nerve conduction velocity (MNCV), but not thermal hypoalgesia displayed in diabetic rats. In addition, chronic treatment with (-)-epicatechin (3 mg/kg, i.p.) did not prevent SOD expression reduction observed in diabetic rats. Finally, the data showed that (-)-epicatechin did not have effects on the motor coordination test and parameters such as glucose and body weight in diabetic rats. Conclusions: Our data suggest that (-)-epicatechin treatment has antiallodynic effects in PDN rats.

 

Citation Format: Quiñonez-Bastidas GN, Calcutt NA, Frizzi K, Rocha-González HI, Granados-Soto V, Murbartián J (2015) (-)-Epicatechin reduces allodynia in rats with painful diabetic neuropathy. [Abstract]. In: Proceedings of the FAPRONATURA 2015; 2015 Sep 21-25; Topes de Collantes, Sancti Spiritus: CSF. J Pharm Pharmacogn Res 3(Suppl. 1): S94. Abstract nr PPP-02.